NMD

ReviR Therapeutics Announces Addition of Dr. Lynne E. Maquat and Dr. Brian Safina to Scientific Advisory Board

Retrieved on: 
Friday, May 13, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Senior, RNA transfection, American Academy, Immunology, Research, John J. Carty Award for the Advancement of Science, Voyager, Disease, National, University of Rochester, The arts, Wolf Prize, Biochemistry, Warren Alpert Foundation Prize, EJC, NMD, Association, Therapy, RNA Society, National Academy of Medicine, National academy, Biophysics, Patent, Wolf Prize in Medicine, Fellow of the American Association for the Advancement of Science, RNA, Genentech, University, MicroRNA, American Association, United States Air Force Scientific Advisory Board, Harvard Medical School, University of California, San Diego, Entrepreneurship, Neuroscience, Drug discovery, Pharmaceutical industry, Medical device, Medicine, Science, Science

ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.

Key Points: 
  • ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.
  • We are honored to welcome Dr. Maquat and Dr. Safina to our Scientific Advisory Board, said Peng Yue, Ph.D., Co-Founder, and Chief Executive Officer of ReviR Therapeutics.
  • Each expert will bring in-depth knowledge of RNA biology as well as drug discovery and development expertise.
  • Dr. Maquat brings to ReviR decades of experience in RNA research.

NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer

Retrieved on: 
Tuesday, May 10, 2022
National Institute of Mental Health, Drug development, NDAS, Business administration, Laboratory, IND, Translational medicine, MG, Columbia University, Myasthenia gravis, Â, Johnson & Johnson, Patient, Pontifical university, Master of Business Administration, FDA, Mental health, Pontifical Catholic University of Chile, Hoffmann-La Roche, Psychiatry, Science, MBA, Neuromuscular Disorders, Head, Development of the nervous system in humans, National Institute, Pharmaceutical industry, MD, NMD

Dr. Quiroz brings twenty years of drug development experience in academia and the pharmaceutical and biotechnology industries.

Key Points: 
  • Dr. Quiroz brings twenty years of drug development experience in academia and the pharmaceutical and biotechnology industries.
  • Dr Jorge A. Quiroz, newly appointed Chief Medical Officer at NMD Pharma, said: It is a great time to be joining NMD Pharma as it concludes its Phase IIa study of NMD670 in myasthenia gravis patients and progresses parallel programs based on the novel and exciting science of ClC-1 inhibition.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: Jorge brings years of experience leading clinical teams and programs, and I am pleased that he is joining NMD Pharma at such a pivotal time.
  • In his new role, Dr Quiroz will be based near Boston, Massachusetts where NMD Pharma has recently expanded its presence.

Skylight Health Completes Largest Acquisition to date and Enters Medicare Advantage Global Risk

Retrieved on: 
Friday, May 6, 2022
TSX Venture Exchange, U.S. Securities and Exchange Commission, Medicare, Neighbor, NASDAQ, GLOBE, Company, VBC, Contract, Time, FLC, Patient, Security (finance), MA, Acquisition, Leadership, Canadian Securities Administrators, NMD, Capitation fee, SOFR, CEO, FFS, Â, Entrepreneurship, Skylight, TTM, Humana, Health insurance

TORONTO, May 06, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (NASDAQ:SLHG; TSXV:SLHG) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, is pleased to announce that further to its press release dated May 3, 2022, it has completed the deal to acquire NeighborMD (NMD) for $8 million and a debt facility of US $20 million.

Key Points: 
  • We are very pleased to close our largest acquisition to date and welcome the team at Neighbour MD into the Skylight Health Group, says Prad Sekar, CEO and Co-Founder of Skylight Health.
  • We are now strongly positioned with risk contracts to begin focusing on our pipeline within Florida that will present Medicare and MA growth.
  • The expected expansion of the risk contracts to existing Skylight practices in Florida represent a significant organic growth opportunity.
  • Skylight Health Group (NASDAQ:SLHG;TSXV:SLHG) is a healthcare services and technology company, working to positively impact patient health outcomes.

adidas and Foot Locker, Inc. Announce New Long-Term Strategic Partnership

Retrieved on: 
Thursday, May 5, 2022
XETRA, Ecosystem, Sportswear, Culture, EMEA, Superstar, Consumer, NEW, Company, NYSE, Adidas, Fear, Champs Sports, Foot Locker, Partnership, Industry, WSS, NMD, Heart, City, Atmos, Eastbay

HERZOGENAURACH, Germany and NEW YORK, May 5, 2022 /PRNewswire/ -- adidas AG (XETRA: ADS.DE) ("adidas"), a global leader in the sporting goods industry, and Foot Locker, Inc. (NYSE: FL) ("Foot Locker"), the New York-based specialty athletic retailer, today announced a new and enhanced partnership built around product innovation, elevated experiences, and deeper consumer connectivity. This enhanced relationship will establish Foot Locker as the lead partner for adidas in the basketball category, accelerate energy and hype launches, as well as include the development and expansion of key franchises across women's, kids, and apparel. Including all Foot Locker banners in North America, EMEA, and Asia-Pacific, the new strategic partnership will target over $2 billion in retail sales by 2025, nearly tripling levels from 2021. In 2022, adidas expects to generate incremental revenues of up to €100 million as a result of the new partnership.

Key Points: 
  • Including all Foot Locker banners in North America, EMEA, and Asia-Pacific, the new strategic partnership will target over $2 billion in retail sales by 2025, nearly tripling levels from 2021.
  • In 2022, adidas expects to generate incremental revenues of up to 100 million as a result of the new partnership.
  • "We are delighted to be deepening our partnership with Foot Locker as we continue to execute our 'Own the Game' strategy," said adidas CEO Kasper Rorsted.
  • adidas and Foot Locker undertake no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise.

adidas and Foot Locker, Inc. Announce New Long-Term Strategic Partnership

Retrieved on: 
Thursday, May 5, 2022
XETRA, Ecosystem, Sportswear, Culture, EMEA, Superstar, Consumer, NEW, Company, NYSE, Adidas, Fear, Champs Sports, Foot Locker, Partnership, Industry, WSS, NMD, Heart, City, Atmos, Eastbay

HERZOGENAURACH, Germany and NEW YORK, May 5, 2022 /PRNewswire/ -- adidas AG (XETRA: ADS.DE) ("adidas"), a global leader in the sporting goods industry, and Foot Locker, Inc. (NYSE: FL) ("Foot Locker"), the New York-based specialty athletic retailer, today announced a new and enhanced partnership built around product innovation, elevated experiences, and deeper consumer connectivity. This enhanced relationship will establish Foot Locker as the lead partner for adidas in the basketball category, accelerate energy and hype launches, as well as include the development and expansion of key franchises across women's, kids, and apparel. Including all Foot Locker banners in North America, EMEA, and Asia-Pacific, the new strategic partnership will target over $2 billion in retail sales by 2025, nearly tripling levels from 2021. In 2022, adidas expects to generate incremental revenues of up to €100 million as a result of the new partnership.  

Key Points: 
  • Including all Foot Locker banners in North America, EMEA, and Asia-Pacific, the new strategic partnership will target over $2 billion in retail sales by 2025, nearly tripling levels from 2021.
  • In 2022, adidas expects to generate incremental revenues of up to 100 million as a result of the new partnership.
  • "We are delighted to be deepening our partnership with Foot Locker as we continue to execute our 'Own the Game' strategy," said adidas CEO Kasper Rorsted.
  • adidas and Foot Locker undertake no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise.

Skylight Health Executes Definitive Agreement to Acquire NeighborMD to Expand in Florida and Enters Medicare Advantage Global Risk

Retrieved on: 
Tuesday, May 3, 2022
Medicare, NASDAQ, GLOBE, Company, Contract, Time, MA, Knowledge, Leadership, NMD, Creditor, Capitation fee, SOFR, CEO, CHS, Growth, TTM, Risk, Acquisition, Health insurance, Risk management, Skylight, Humana

TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (NASDAQ: SLHG; TSXV: SLHG) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, today announces the execution of a definitive agreement to acquire NeighborMD (NMD) which will close concurrently with a debt facility of US $20 million that the Company has arranged with a New York-based lender.

Key Points: 
  • NeighborMD (NMD) will add 9 practices across Central and Southern Florida with over 2,400 owned and affiliated global capitated risk lives.
  • Based in central and southern Florida, NMD operates 9 owned practices offering primary care services to over 5,000 lives.
  • Within these, NMD has over 1,100 MA lives in full-risk contracts with two leading healthcare payors in Florida, Humana, and CarePlus.
  • The expected expansion of the risk contracts to existing Skylight practices in Florida represents a significant organic growth opportunity.

NMD Pharma expands its US presence

Retrieved on: 
Tuesday, May 3, 2022
MG, NMD, Myasthenia gravis, Neuromuscular Disorders, Degenerative disease, Patient, Growth, Phase, Fine chemical, Pharmaceutical industry

Aarhus, Denmark, 3 May 2022 NMD Pharma A/S, a clinical stage biotech company developing first in class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that it has expanded its presence in the US with the creation of a new US subsidiary, NMD Pharma US, Inc.

Key Points: 
  • Aarhus, Denmark, 3 May 2022 NMD Pharma A/S, a clinical stage biotech company developing first in class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that it has expanded its presence in the US with the creation of a new US subsidiary, NMD Pharma US, Inc.
    NMD Pharma US, Inc. is incorporated in Delaware State, but NMD Pharmas activity will be mostly centered around the Boston, Massachusetts area.
  • The Companys expansion into the US comes as it starts recruiting for several senior US-based roles and plans for an increase in R&D activity, including clinical trials.
  • In February, NMD Pharma raised 35 million in a new financing to complete the ongoing Phase IIa trial of NMD670 in patients with MG and to expand its clinical programs into several neuromuscular diseases.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: Our expansion in the worlds largest pharmaceutical market comes at an important time for our business as we look ahead to the results of the Phase IIa trial of NMD 670 anticipated later this year.

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

Retrieved on: 
Monday, May 2, 2022
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Optical, Science, Other Science, COVID-19, U.S. Securities and Exchange Commission, Mutation, Private Securities Litigation Reform Act, Twitter, Nasdaq, Asos, Targeted molecular therapy for neuroblastoma, RNA, Company, Retinal ganglion cell, Haploinsufficiency, Stoke, Research, Eye, TANGO, ARVO, ADOA, RGC, Injection, Patient, Security (finance), Association, Incidence, Association for Research in Vision and Ophthalmology, Severe cognitive impairment, Tissue, Significance, Potency (pharmacology), Founder effect, Dravet syndrome, ASO, Disease, NMD, Life, RNA transfection, IVT, Annual general meeting, Central nervous system, Therapy, Vaccine, Pharmaceutical industry, Ophthalmology, OPA1

Stoke Therapeutics, Inc. (Nasdaq: STOK), abiotechnologycompanydedicatedtoaddressingthe underlying causeof severe diseases by upregulating protein expression with RNA-based medicines, todayannounced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), abiotechnologycompanydedicatedtoaddressingthe underlying causeof severe diseases by upregulating protein expression with RNA-based medicines, todayannounced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002.
  • Target engagement and OPA1 protein increases were sustained for at least eight weeks post-injection.
  • A dose-related increase in OPA1 protein was also detected in retinal ganglion cells (RGCs) of NHPs treated with STK-002.
  • An estimated 65% to 90% of cases are caused by mutations in the OPA1 gene, most of which lead to a haploinsufficiency resulting in 50% OPA1 protein expression and disease manifestation.

AMRA Medical, Daiichi Sankyo and NCNP joint MRI-based muscle research accepted for poster presentation at 2022 MDA Conference

Retrieved on: 
Monday, March 14, 2022
Biomarker, Patient, Research, Daiichi Sankyo, Therapy, Symbiosis, Conference, NMDS, Neurology, Human, Precision medicine, Multimedia, Degenerative disease, NMD, MDA, Magnetic resonance imaging, Technology, Episcopal conference, National Center for Spinal Disorders, Poster, Neuromuscular disease, Radiology, MRI, Medical imaging, Psychiatry

The MDA conference will highlight the latest preclinical research, clinical trials, and clinical management in NMDs and the impact on the NMD community.

Key Points: 
  • The MDA conference will highlight the latest preclinical research, clinical trials, and clinical management in NMDs and the impact on the NMD community.
  • Volumetric MRI-based analysis of muscle volume and muscle fat has emerged as a promising technique for monitoring disease progression and evaluating treatment response in humans.
  • Previously, AMRA optimized its MRI protocol and image analysis technology for volumetrically analyzing muscle volume and muscle fat in various NMD patient populations.
  • AMRA, Daiichi Sankyo, and the NCNP demonstrated how well that approach generalizes to sIBM in this repeatability study.

Antisense Therapeutics to present poster at world’s largest NMD conference

Retrieved on: 
Wednesday, March 9, 2022
Life, Muscular Dystrophy Association, Patient, Research, Life expectancy, Duchenne muscular dystrophy, Conference, Lists of diseases, Genetic disorder, DMD, Weakness, AWY, CDT, NMD, GLOBE, ANP, MDA, Drug discovery, Fibrosis, Degenerative disease, Episcopal conference, Therapy, Cartilage, Poster, Pharmaceutical industry

New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week.

Key Points: 
  • New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week.
  • It is marked by progressive muscular weakness and degeneration, with most patients needing a wheelchair by their early teenage years.
  • Dr. Tachas will present the poster whose abstract is now online between 6:00 PM and 8:00 PM (CDT) from March 13 to 15.
  • The goal of the MDA conference is to support the development of better care and treatments for neuromuscular diseases (NMD).